Gravar-mail: TMOD-17. A NOVEL ADENOVIRAL-PERMISSIVE, IMMUNOCOMPETENT HAMSTER MODEL TO EVALUATE ONCOLYTIC ADENOVIRAL THERAPY FOR GLIOBLASTOMA